secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0000950170-22-017380
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma Q2 2022 cash $89.3M; initiates Phase 3 sarcoidosis study
--------------------------------------------------------------------

- Cash, restricted cash, cash equivalents and investments $89.3M as of June 30, 2022.
- R&D expenses $9.1M, G&A expenses $3.4M for Q2 2022; no revenue reported.
- First sites initiated in global Phase 3 EFZO-FIT study for pulmonary sarcoidosis.
- FDA Fast Track designation granted for efzofitimod in pulmonary sarcoidosis.
- Company on track to enroll first patient in Q3 2022; 28.1M shares outstanding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017022017380/0000950170-22-017380-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017022017380/life-20220815.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-017380

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer